Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$14.43 USD
+0.29 (2.05%)
Updated Mar 27, 2024 04:00 PM ET
After-Market: $14.44 +0.01 (0.07%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Price, Consensus and EPS Surprise
TEVA 14.43 +0.29(2.05%)
Will TEVA be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TEVA
Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US
J&J (JNJ) Seeks Expanded Use of Tremfya for Ulcerative Colitis
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
Other News for TEVA
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
Teva on track for seventh straight day of gains
Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In'
Teva Pharmaceutical Industries: Potential Outweighs Concerns
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month